Today is the first day of the subscription period for Cereno Scientific"s rights issue with the aim of preparing for and initiating the Phase-2 study. More information about the issue can be found on the Company"s website, https://www.cerenoscientific.se/investor-relations/foretradesemission-2019/, and on Mangold’s website, www.mangold.se/emission/inbjudan-till-teckning-av-b-aktier-i-cereno-scientific-ab-publ, where it’s possible to subscribe using Bank-ID.

In connection with the Company"s rights issue, Cereno Scientific will participate at the event Småbolagsdagen and the event Mangold´s Investerardagen, both events will be held in Stockholm.

During Småbolagsdagen held on June 3, the Company"s CEO Sten R. Sörensen will present 14:00 - 14:30 in room 4. Representatives from the Company will be available prior to the presentation to answer questions and talk to investors.

For those who do not have the opportunity to visit Småbolagsdagen, Cereno Scientific will on the same date, June 3, also participate at Mangold´s event Investerardagen. The Company´s CEO and CMO will give a presentation that afternoon at 15:50. After the presentation, participants will have the opportunity to ask questions and speak with representatives from the Company. At this event, 9 other companies will also participate and present.

See below for further information about each event and information on how to register:

Småbolagsdagen
Date: Monday June 3
Time: 08:00 - 18:00, Cereno Scientific will hold a presentation in room 4 during 14:00 – 14:30
Location: Sheraton Hotel, Tegelbacken 6, Stockholm
For more information and registration: https://www.aktiespararna.se/smabolagsdagen
The presentation can also be viewed live at: www.aktiespararna.se/tv/live

Mangold’s Investerardag
Date: Monday June 3
Time: 11:00 - 19:00, Cereno Scientific will hold presentation 15:50 - 16:10
Location: Scandic Anglais, Humlegårdsgatan 23, Stockholm
For more information: https://www.mangold.se/investerdagen/
Register at: investerardagen@mangold.se

For further information, please contact:

Daniel Brodén  – CFO
Tel: +46 768 66 77 87
E-mail: info@cerenoscientific.com
www.cerenoscientific.se

About Cereno Scientific AB
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.